{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060716","form_type":"8-K","ticker":"COYA","cik":"0001835022","company_name":"Coya Therapeutics, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.888923+00:00","generated_at":"2026-06-08T10:40:00.558981+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Coya reports Q3 net loss $3.4M, cash $10.9M; Phase 2 AD topline due summer 2024","bullets":["Net loss $3.4M ($0.34/share) vs $4.0M ($1.55/share) in Q3 2022; cash $10.9M up from $5.9M at Dec 2022.","R&D expenses $1.6M, G&A $2.0M; net loss per share improved due to increase in shares outstanding to 9.95M.","Completed enrollment (38 patients) in Phase 2 double-blind placebo-controlled trial of LD IL-2 in Alzheimer's; topline data expected summer 2024.","Plan to submit IND for Phase 2 trial of COYA 302 in ALS in 1H 2024; also licensed exosome engineering technology from Carnegie Mellon.","Appointed Dieter Weinand to board, Dr. Fred Grossman as President & CMO, and Dr. Merit Cudkowicz as clinical advisor in recent months."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060716","json":"https://secwatch.observer/filing/0000950170-23-060716.json","markdown":"https://secwatch.observer/filing/0000950170-23-060716.md","text":"https://secwatch.observer/filing/0000950170-23-060716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1835022/000095017023060716/0000950170-23-060716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1835022/000095017023060716/coya-20231108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T10:40:00.558981+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"005b950d424c6c41df14ea18772fd350fb2b0fd8","claim":"Coya Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.","evidence_excerpt":"On November 8, 2023, Coya Therapeutics, Inc. (the “Company”) issued a press release disclosing certain information regarding its results of operations for the fiscal quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1835022/000095017023060716/0000950170-23-060716-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}